Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding
Recruiting
Observational Study
Arteriovenous Malformation
Bleeding
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Observational
- Participants needed
- 162 (estimated)
- Sponsor
- Beijing Tiantan Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cerebral arteriovenous malformation (AVM) is the leading cause of brain hemorrhage in young adults, characterized by sudden onset and rapid progression. The hybrid neurosurgical operating room is a diagnostic and therapeutic platform that integrates neurointervention and microneurosurgery, offering advantages such as one-stop rapid treatment and multimodal therapeutic approaches.
This study aims …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Head CT confirmed cerebral hemorrhage, with indications for emergency surgery
* Head CTA suggested that the responsible lesion may be cerebral arteriovenous malformation
* Spetzler-Martin classification 1 to 4; Cerebral arteriovenous malformation Spetzler-Martin classification…
Contacts